Stay updated with breaking news from Johan Vansteenkiste. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...
LIÈGE, Belgium & GRENOBLE, France, April 08, 2024--PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.
E-Mail Lugano, Switzerland; Denver, CO, USA, 12 March 2021 - The European Lung Cancer Congress 2021, the annual event devoted to advance the quality of lung cancer treatment, will be held as a virtual meeting (25-27 March). (1) More than 200 studies will be presented (oral or e-poster presentations) and published online as a supplement of the Journal of Thoracic Oncology. (2) Programme highlights New perspectives in the treatment of small cell lung cancer and mesothelioma, including novel agents and prospects for chemotherapy, radiotherapy and immunotherapy Lung cancer prevention, with a...
Credit: ESMO credit Lugano, Switzerland; Denver, CO, USA, 11 March 2021 - The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have the pleasure of announcing that the Heine H. Hansen Award 2021 is conferred on Johan Vansteenkiste, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at University Hospitals Leuven. An internationally renowned clinical researcher and devoted educator in the field of lung cancer, Vansteenkiste will have the opp...